Yumanity Therapeutics (YMTX) News Today → Biden Nomination CANCELED? (From The Freeport Society) (Ad) Free YMTX Stock Alerts $0.49 +0.01 (+2.10%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsSocial MediaStock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 2:34 AM | americanbankingnews.comYumanity Therapeutics (NASDAQ:YMTX) Trading Up 1.8%March 20, 2024 | seekingalpha.comJSPR Jasper Therapeutics, Inc.November 3, 2023 | morningstar.comCara Therapeutics Inc CARAOctober 6, 2023 | thestreet.comYumanity Therapeutics Inc.July 5, 2023 | thestreet.comFormer Onyx CEO Returns to Biotech to Launch Boston Start UpMay 1, 2023 | bizjournals.comKineta raises $6M through registered direct offeringFebruary 22, 2023 | finance.yahoo.comColorectal Cancer Therapeutics Market Size to Surpass US$ 24.58 Billion by 2030 - Growth Plus ReportsDecember 26, 2022 | msn.comYumanity Therapeutics's Return On Capital Employed InsightsDecember 20, 2022 | bizjournals.comKineta finalizes reverse merger with Yumanity, secures additional fundingDecember 5, 2022 | finance.yahoo.comYumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with KinetaDecember 5, 2022 | investorplace.comWhy Is Yumanity Therapeutics (YMTX) Stock Up Today?November 14, 2022 | finanznachrichten.deYumanity Therapeutics Inc: Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate DevelopmentsNovember 14, 2022 | finance.yahoo.comYumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate DevelopmentsNovember 10, 2022 | finance.yahoo.comYumanity Therapeutics Announces Effectiveness of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta, Inc.August 29, 2022 | finance.yahoo.comYumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with KinetaAugust 4, 2022 | finance.yahoo.comYumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate DevelopmentsJune 8, 2022 | finance.yahoo.comInside Kineta's plans after unveiling reverse merger dealJune 7, 2022 | bizjournals.comSeattle biotech Kineta to go public in merger deal with Yumanity TherapeuticsJune 7, 2022 | msn.comShort Volatility Alert: Yumanity Therapeutics, Inc.June 6, 2022 | marketwatch.comYumanity to Sell Neurosciences Candidates, Merge With Kineta >YMTXJune 6, 2022 | seekingalpha.comYumanity stock soars 46% on all-stock merger with Kineta; lead product sale to J&J for $26MJune 6, 2022 | nasdaq.comYumanity Therapeutics To Sell 2 Product Candidates For $26 Mln In Cash; Inks Merger Deal With KinetaJune 6, 2022 | finance.yahoo.comYumanity Therapeutics Shares Trading Higher Today - Read Here WhyJune 6, 2022 | investorplace.comWhy Is Yumanity Therapeutics (YMTX) Stock Up 50% Today?June 6, 2022 | finance.yahoo.comYumanity Therapeutics Announces Definitive Agreements for Two Strategic TransactionsJune 2, 2022 | benzinga.com53 Stocks Moving In Thursday's Mid-Day SessionMay 14, 2022 | seekingalpha.comYumanity Therapeutics GAAP EPS of -$1.24, revenue of $1.02MMay 13, 2022 | finance.yahoo.comYumanity Therapeutics (YMTX) Reports Q1 Loss, Misses Revenue EstimatesMay 13, 2022 | finance.yahoo.comYumanity Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate DevelopmentsMarch 25, 2022 | benzinga.comLooking Into Yumanity Therapeutics's Return On Capital EmployedMarch 24, 2022 | seekingalpha.comYumanity Therapeutics GAAP EPS of -$3.84, revenue of $8.04MMarch 24, 2022 | finance.yahoo.comYumanity Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate DevelopmentsFebruary 17, 2022 | seekingalpha.comYumanity to cut 60% of workforce as it evaluates strategic alternativesFebruary 17, 2022 | finance.yahoo.comYumanity Therapeutics Exploring Strategic Alternatives to Enhance Shareholder Value and Announces RestructuringFebruary 17, 2022 | marketbeat.comTrading was temporarily halted for "YMTX" at 08:02 AM with a stated reason of "News pending."January 19, 2022 | marketwatch.comYumanity Says FDA Puts Partial Hold on YTX-7739 Studies >YMTXJanuary 19, 2022 | marketwatch.comYumanity Therapeutics Shares Tumble on Partial FDA Study Hold >YMTXJanuary 19, 2022 | seekingalpha.comYumanity's multi-dose clinical trial put on hold by FDA, stock slides 12%January 19, 2022 | msn.comYumanity Shares Fall On FDA Hold On Multidose Trials In Parkinson's DiseaseJanuary 19, 2022 | finance.yahoo.comYumanity Reports Partial Clinical Hold by U.S. FDA on Multidose Clinical Trials for YTX-7739January 18, 2022 | marketbeat.comYumanity Therapeutics (NASDAQ:YMTX) Upgraded to "Buy" by Zacks Investment ResearchZacks Investment Research upgraded Yumanity Therapeutics from a "hold" rating to a "buy" rating and set a $3.00 price target for the company in a research report on Tuesday.January 11, 2022 | finance.yahoo.comYumanity’s Approach to Neurodegenerative Diseases Validated by Two External CollaborationsJanuary 5, 2022 | marketbeat.comYumanity Therapeutics, Inc. (NASDAQ:YMTX) Short Interest Down 61.4% in DecemberYumanity Therapeutics, Inc. (NASDAQ:YMTX) was the target of a significant drop in short interest in December. As of December 15th, there was short interest totalling 61,200 shares, a drop of 61.4% from the November 30th total of 158,400 shares. Based on an average daily trading volume, of 175,700 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.9% of the shares of the stock are sold short.January 4, 2022 | finance.yahoo.comYumanity Therapeutics to Present at the H.C. Wainwright BioConnect ConferenceDecember 31, 2021 | realmoney.thestreet.comYumanity Therapeutics, Inc. (YMTX)December 29, 2021 | nasdaq.comYumanity Therapeutics Inc Shares Fall 0.7% Below Previous 52-Week Low - Market MoverNovember 16, 2021 | finance.yahoo.comYumanity Therapeutics to Present at Multiple Upcoming November Investor ConferencesNovember 15, 2021 | chron.comYumanity: Q3 Earnings SnapshotNovember 15, 2021 | finance.yahoo.comYumanity Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate DevelopmentsNovember 12, 2021 | fxstreet.comMid-afternoon market update: Nasdaq tumbles 300 points, Pubmatic shares gain after Q3 results Get Yumanity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for YMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address A ‘DeFi Summer’ Projected! (Ad)Top analysts are predicting DeFi coins to see massive gains in the coming months… During this dubbed ‘DeFi Summer…’ A coin that has been called the “DeFi pioneer” is poised to shoot up 3-7x! Just click here to learn how you can access this coin right now. YMTX Media Mentions By Week YMTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. YMTX News Sentiment▼0.000.54▲Average Medical News Sentiment YMTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. YMTX Articles This Week▼10▲YMTX Articles Average Week Get Yumanity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for YMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Adial Pharmaceuticals News Lixte Biotechnology News Enveric Biosciences News Oragenics News Kintara Therapeutics News Hillstream BioPharma News Xenetic Biosciences News Kineta News Ainos News Hoth Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:YMTX) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersHow Biden has already won 2024Porter & Company348 million Americans lives to END as we know it?The Oxford ClubBiden Nomination CANCELED?The Freeport Society4 Cryptos BETTER than BitcoinTrue Market InsidersCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm PressWhy Is Gold On a MASSIVE rally? Huge AlertsInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Yumanity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
